Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model

Recombinant hirudin (r-hirudin) is a new anticoagulant with specific antithrombin activity independently of antithrombin III. Low molecular weight heparins (LMWH) exert predominantly anti-Xa activity. Therefore, we hypothesized that combined administration of r-hirudin and LMWH would induce a stronger antithrombotic effect as compared to r-hirudin administered alone or combined with unfractionated heparin. To assess the effect on thrombus growth, we determined the accretion of 125I-labeled fibrinogen onto autologous non-radioactive thrombi preformed in the jugular veins of rabbits. The rabbits received unfractionated heparin (80 anti-factor Xa U), LMWH (80 anti-factor Xa U) or r-hirudin (0.3, 5.0 and 10.0 mg/kg) either separately or by combined infusion for a 3 h period. R-Hirudin reduced the thrombus growth in a dose dependent fashion. The combined administration of 80 anti-Xa U LMWH and r-hirudin at a dose of 0.3 mg/kg resulted in a stronger antithrombotic effect as compared to the combined infusion of unfractionated heparin and r-Hirudin (thrombus growth: 14.3% +/- 6.0 vs 28.9% +/- 6.5; p = 0.001). This difference in additive antithrombotic effect of 80 anti-Xa U LMWH versus unfractionated heparin on r-hirudin was also observed when LMWH was combined with 5.0 mg/kg and 10.0 mg/kg r-hirudin versus unfractionated heparin combined with r-hirudin (thrombus growth: 16.4% +/- 1.6 vs 29.1% +/- 3.9; p = 0.01 and 10.1% +/- 1.8 vs 20.4% +/- 4.5; p = 0.001, respectively). In conclusion, this study showed an additive antithrombotic effect of LMWH on the thrombus growth reducing effect of r-hirudin.(ABSTRACT TRUNCATED AT 250 WORDS)

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Peer-reviewed research on leech salivary pharmacology and bioactive peptides relevant to anticoagulation. Indexed in PubMed and verified against the NCBI record.

Leech-derived molecules this paper discusses, each with a full profile in the ASH compound registry:

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

More peer-reviewed studies in Speichel-Pharmakologie.

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• 434 Salivary Proteins — Integrated Proteomics of Hirudo medicinalis — Liu et al. (2019)
• Medicinal Leech Genome Assembly — Anticoagulant Gene Catalog — Kvist et al. (2020)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• [Research progress in hirudin fusion protein--review] — Zhang C et al. (2007)
• A unique proteolytic fragment of human fibrinogen containing the A alpha COOH-terminal domain of the native molecule — Kirschbaum NE, Budzynski AZ (1990)
• Updates on Use and Monitoring of Direct Thrombin Inhibitors — Navaei A et al. (2026)
• Production and functional characteristics of a novel hirudin variant with better anticoagulant activities than bivalirudin — Ge P et al. (2025)
• Traditional Chinese medicine in the treatment of diabetic kidney disease: the mechanisms of signaling pathways regulations — Li W et al. (2026)
• Prostaglandin E1 is an efficient molecular tool for forest leech blood sucking — Zheng F et al. (2021)

Browse all ASH-analysed research →